✦ LIBER ✦

A Single-Dose Pharmacokinetic Study of Lasofoxifene in Healthy Volunteers and Subjects With Mild and Moderate Hepatic Impairment

✍ Scribed by Bramson, Candace; Ouellet, Daniele; Roman, Doina; Randinitis, Edward; Gardner, Mark J.

Book ID: 120166849
Publisher: Sage Publications
Year: 2006
Tongue: English
Weight: 110 KB
Volume: 46
Category: Article
ISSN: 0091-2700
DOI: 10.1177/0091270005283278

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PP194—Pharmacokinetics of Selexipag in S

PP194—Pharmacokinetics of Selexipag in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects

✍ Fischer, N.; Kaufmann, P.; Bruderer, S.; Ulč, I.; Dingemanse, J. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 78 KB

Multiple-Dose Pharmacokinetics and Safet

Multiple-Dose Pharmacokinetics and Safety of Desloratadine in Subjects With Moderate Hepatic Impairment

✍ Gupta, Samir K.; Kantesaria, Bhavna; Wang, Zaiqi 📂 Article 📅 2007 🏛 Sage Publications 🌐 English ⚖ 129 KB

Single-dose pharmacokinetics of nefazodo

Single-dose pharmacokinetics of nefazodone in healthy young and elderly subjects and in subjects with renal or hepatic impairment

✍ R. H. Barbhaiya; D. S. Greene; U. A. Shukla 📂 Article 📅 1995 🏛 Springer 🌐 English ⚖ 658 KB

The single-dose pharmacokinetics of nefazodone (NEF) and its metabolites hydroxynefazodone (HO-NEF) and m-chlorophenylpiperazine (mCPP) were examined in 12 healthy younger subjects < 55 years of age (YNG), 12 elderly subjects > 65 years of age (ELD), 12 patients with biopsy proven hepatic cirrhosis

7055 POSTER A Phase 1 Single-dose Open-l

7055 POSTER A Phase 1 Single-dose Open-label Pharmacokinetic (PK) Study of Abiraterone Acetate (AA) in Male Subjects With Mild or Moderate Hepatic Impairment

✍ Marbury, T.; Stonerock, R.; Acharya, M.; Gonzalez, M.; Jiao, J.; Breeding, J.; H 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 44 KB

Effect of mild and moderate hepatic impa

Effect of mild and moderate hepatic impairment on azimilide pharmacokinetics following single dose oral administration

✍ Alfred E. Corey; Jeffrey R. Agnew; Eileen C. King; Nikhil J. Parekh; James H. Po 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB

Azimilide dihydrochloride (75-125 mg/day) is currently being developed for use in prolonging the time to recurrence of atrial fibrillation/flutter and for reducing the frequency of shocks in patients with an implantable cardioverting defibrillator. This study investigated the influence of mild and m

P0586 A COMPARISON OF THE SINGLE-DOSE PH

P0586 A COMPARISON OF THE SINGLE-DOSE PHARMACOKINETICS AND SAFETY OF SAXAGLIPTIN IN SUBJECTS WITH HEPATIC IMPAIRMENT AND IN HEALTHY SUBJECTS

✍ David W Boulton; Angela Tang; Chirag Patel; Lorna Castaneda; Uli Frevert; Li Li; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 74 KB